Patent · US Active

PDE5 inhibitor powder formulations and methods relating thereto

US12364701B2 · kind B2 · utility

0Cited by

52References

33Claims

0Family size

Assignee

Respira Therapeutics, Inc. · US

Inventors

Zhen Xu · Ann Arbor, US
Hugh Smyth · Austin, US
Aileen Gibbons · New York, US
Revati Shreeniwas · Palo Alto, US
Pravin Soni · Union City, US
Dan Deaton · Apex, US
James B. Hannon · Somers, US
Stephen Lermer · Austin, US
Robert Curtis · Santa Fe, US
Martin Donovan · Austin, US

Key dates

Filing date	Jan 22, 2024
Grant date	Jul 22, 2025
Priority date	—
Expiry date	Jan 22, 2044

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.